Clinical trials: Neoplasm, Esophagus
Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia
Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)
This is a prospective randomized clinical trial examining how IRIS (Intelligent Real-time Image Segmentation) affects biopsy patterns in VLE (Volumetric laser endomicroscopy).
- Conditions
- Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia, Barrett's Esophagus With Low Grade Dysplasia, Barrett's Esophagus With High Grade Dysplasia
- Trial name
- NCT03814824
- Testing
- IRIS (Intelligent real-time image segmentation), VLE (Volumetric laser endomicroscopy)
- Where
- 3 sites in United States
- Volunteers
- 148 people
- Sponsor
- Northwell Health
Dysphagia, Dysplasia
Esophageal Cytology With FISH in Detecting Esophageal Cancer
This clinical trial studies whether esophageal cytology plus fluorescence in situ hybridization (FISH) is equal to or better than esophago-gastro-duodenoscopy (EGD) or upper endoscopy for the early detection of esophageal cancer.
- Conditions
- Dysphagia, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02100189
- Testing
- Cytology Specimen Collection Procedure, Esophagogastroduodenoscopy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Atrial Fibrillation, Esophageal Carcinoma
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
This phase II trial studies how well amiodarone works in the prevention of atrial fibrillation (AF) after a minimally invasive esophagectomy (MIE) in patients with esophageal cancer.
- Trial name
- NCT06067438
- Testing
- Amiodarone Hydrochloride, Saline
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- OHSU Knight Cancer Institute
Esophagus Cancer, Stomach Cancer
Effects of S-1 and Capecitabine on Coronary Artery Blood Flow
Fluoropyrimidine chemotherapy agents , such as 5-fluorouracil and capecitabine, are occasionally associated with cardiac toxicity.
- Conditions
- Esophagus Cancer, Stomach Cancer, Small Bowel Cancer, Colon Cancer
- Trial name
- FluoHeart (NCT02216149)
- Testing
- S-1, Capecitabine, Oxaliplatin
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- Heikki Joensuu
Esophageal Squamous Cell Carcinoma
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
This study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve…
- Trial name
- ARMADILLO (NCT04328948)
- Testing
- Chemoradiotherapy
- Where
- Japan
- Volunteers
- 280 people
- Sponsor
- National Cancer Center, Japan
Esophageal Malignant Neoplasm, Local Recurrence
Clinical Control Study of Immunotherapy and Concurrent Chemoradiotherapy in Patients With Esophageal Cancer Recurrence
Esophageal cancer is still a serious threat to human life and health. China in particular. Relapse and metastasis are important causes of treatment failure.
- Trial name
- NCT04404491
- Testing
- Procedural death 1, Capecitabine, Radiotherapy
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Cancer
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic…
- Trial name
- NCT00003326
- Testing
- paclitaxel
- Where
- 30 sites in United States
- Volunteers
- 100 people
- Sponsor
- Theradex
Esophageal Cancer
Discovering Patterns in Experiences of Patients in Esophageal Cancer Clinical Research
Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05831150
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Esophageal Cancer, Chemoradiotherapy
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
This trial is a prospective, randomized, controlled, multicenter, phase II clinical study to evaluate the efficacy and safety of sintilimab as consolidation therapy in elderly patients with esophageal cancer who did not progress…
- Conditions
- Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
- Trial name
- NCT06413342
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 191 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer…
- Trial name
- NCT05163483
- Testing
- Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Ruihua Xu
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Conditions
- Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors
- Trial name
- NCT04000529
- Testing
- TNO155, Spartalizumab, Ribociclib
- Where
- 10 sites in United States, Australia and 7 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma (ESCC)
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This study is designed to assess the efficacy and safety of QLC5508 in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with…
- Trial name
- NCT07463573
- Testing
- QLC5508, Investigator's Choice of Chemotherapy (docetaxel, paclitaxel, or Irinotecan Hydrochloride)
- Where
- China
- Volunteers
- 466 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Esophageal Cancer, Esophageal Adenocarcinoma
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Rationale: For locally advanced esophageal cancer the standard treatment consists of 5 weeks of neoadjuvant chemoradiotherapy (nCRT) followed by surgery.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
- Trial name
- PRIDE (NCT03474341)
- Testing
- MRI, PET-CT, Endoscopy
- Where
- 4 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus…
- Trial name
- STELLAR01 (NCT07530094)
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Ning Jiang, M.D./Ph.D.
Colon Carcinoma, Barrett Esophagus
Safety and Feasibility of Immuno-OCT
To improve detection of premalignant lesions in the gastrointestinal tract (the rectum and the esophagus) there is a need for better endoscopic visualization and the ability for targeted biopsies.
- Conditions
- Colon Carcinoma, Barrett Esophagus, Gastrointestinal Dysplasia
- Trial name
- DETOUR (NCT06008522)
- Testing
- Bevacizumab-800CW
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Esophageal Cancer
Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy
Esophageal carcinoma is an aggressive malignancy with poor prognosis. Surgical resection remains the most effective method for this malignant disease.
- Trial name
- NCT02448966
- Testing
- open esophagectomy, Minimally invasive esophagectomy
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chinese Academy of Medical Sciences
Epidural Block, Oesophageal Cancer
The Hemodynamic Effect Between Two Types of Anesthesia in Esophageal Surgery
Continuous Paravertebral block (PVB) was reported to provide less episodes of hypotension than continuous thoracic epidural block (TEB).
- Conditions
- Epidural Block, Oesophageal Cancer, Oesophagectomy
- Trial name
- HEMOBLOC (NCT03185403)
- Testing
- paravertebral block, thoracic epidural block, ropivacaine
- Where
- France
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma.
- Conditions
- Superficial Esophageal Cancer, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Barretts Esophagus With Dysplasia
- Trial name
- FEO (NCT07343869)
- Where
- France
- Volunteers
- 750 people
- Sponsor
- Société Française d'Endoscopie Digestive
Esophageal Cancer
A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction
Preoperative chemoradiotherapy followed by surgery has been accepted as the standard of care for resectable adenocarcinoma of the esophagus and esophagogastric junction (EGJ).
- Trial name
- BoRgES (NCT04269083)
- Testing
- BIRC3
- Volunteers
- 128 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
Esophageal Cancer
A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer
This is a phase 1 study to evaluate safety and tolerability of Telomelysin (OBP-301) in combination with radiation therapy in patient with esophageal cancer who are not applicable to standard therapy.
- Trial name
- NCT03213054
- Testing
- OBP-301, Radiation
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Oncolys BioPharma Inc